| Withdrawn | Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Depressive Disorder, Major | Phase 3 | 2019-07-01 |
| Completed | Assessment of Effect of Rapastinel on Driving Performance Driving Performance | Phase 1 | 2018-11-05 |
| Completed | Assessment of Abuse Potential of Rapastinel in Humans Human Abuse Potential | Phase 1 | 2018-11-01 |
| Terminated | Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) Depressive Disorder, Major | Phase 3 | 2018-10-30 |
| Terminated | Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) Depressive Disorder, Major | Phase 3 | 2018-08-23 |
| Terminated | Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) Depressive Disorder, Major | Phase 3 | 2018-08-02 |
| Terminated | Study of Rapastinel as Monotherapy in Patients With MDD Depressive Disorder, Major | Phase 3 | 2018-06-15 |
| Terminated | A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder Depressive Disorder, Major | Phase 2 | 2017-12-15 |
| Completed | Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder Depressive Disorder, Major | Phase 3 | 2017-02-03 |
| Completed | A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Dis Depressive Disorder, Major | Phase 3 | 2016-11-13 |
| Completed | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) Depressive Disorder, Major | Phase 3 | 2016-11-02 |
| Completed | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) Depressive Disorder, Major | Phase 3 | 2016-11-01 |
| Completed | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) Depressive Disorder, Major | Phase 3 | 2016-10-15 |
| Completed | Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers Major Depressive Disorder | Phase 1 | 2015-02-01 |
| Terminated | Open Label Extension for GLYX13-C-202, NCT01684163 Major Depressive Disorder | Phase 2 | 2014-09-08 |
| Completed | Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder Major Depressive Disorder | Phase 2 | 2014-03-01 |
| Completed | Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers Healthy | Phase 1 | 2013-05-01 |
| Completed | Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants Major Depressive Disorder | Phase 2 | 2012-11-01 |
| Completed | Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression Major Depressive Disorder | Phase 2 | 2011-05-01 |
| Completed | Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers Healthy | Phase 1 | 2009-11-01 |